Avanir Pharmaceuticals, Inc. (AVNR) Reports In-Line Q4 EPS Loss of $0.14

Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) reported Q4 EPS of ($0.14), in-line with the analyst estimate of ($0.14). Revenue for the quarter came in at $4.8 million versus the consensus estimate of $4.49 million.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c